- Home
- VRTS vs PVLA Comparison
VRTS vs PVLA Comparison
Compare VRTS & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRTS | PVLA |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRTS | PVLA |
|---|---|---|
| Price | $174.49 | $96.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 17 |
| Target Price | ★ $176.40 | $145.24 |
| AVG Volume (30 Days) | 76.8K | ★ 319.0K |
| Earning Date | 01-30-2026 | 11-11-2025 |
| Dividend Yield | ★ 5.60% | N/A |
| EPS Growth | ★ 18.44 | N/A |
| EPS | ★ 19.47 | N/A |
| Revenue | ★ $878,336,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $142.18 | $12.02 |
| 52 Week High | $215.90 | $114.69 |
Technical Indicators
Market Signals| Indicator | VRTS | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 62.86 | 48.25 |
| Support Level | $163.88 | $82.38 |
| Resistance Level | $171.41 | $105.54 |
| Average True Range (ATR) | 4.31 | 8.86 |
| MACD | 0.95 | -1.24 |
| Stochastic Oscillator | 90.03 | 35.96 |
Price Performance
Historical ComparisonAbout VRTS Virtus Investment Partners Inc.
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.